Chengdu Kanghua Biological Products (SHE:300841) — Market Cap & Net Worth
Market Cap & Net Worth: Chengdu Kanghua Biological Products (300841)
Chengdu Kanghua Biological Products (SHE:300841) has a market capitalization of $1.07 Billion (CN¥7.32 Billion) as of October 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #8563 globally and #2031 in its home market, demonstrating a 3.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Kanghua Biological Products's stock price CN¥56.36 by its total outstanding shares 129946899 (129.95 Million).
Chengdu Kanghua Biological Products Market Cap History: 2020 to 2026
Chengdu Kanghua Biological Products's market capitalization history from 2020 to 2026. Data shows growth from $3.73 Billion to $1.07 Billion (4.59% CAGR). Check Chengdu Kanghua Biological Products share price for real-time trading data and today's change.
Chengdu Kanghua Biological Products Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Kanghua Biological Products's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Chengdu Kanghua Biological Products for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.72x
Chengdu Kanghua Biological Products's market cap is 0.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.60x
Chengdu Kanghua Biological Products's market cap is 2.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.73 Billion | $1.04 Billion | $408.05 Million | 3.60x | 9.15x |
| 2021 | $2.55 Billion | $1.29 Billion | $829.48 Million | 1.98x | 3.08x |
| 2022 | $1.55 Billion | $1.45 Billion | $598.07 Million | 1.07x | 2.59x |
| 2023 | $1.43 Billion | $1.58 Billion | $509.22 Million | 0.91x | 2.81x |
| 2024 | $1.04 Billion | $1.43 Billion | $398.65 Million | 0.72x | 2.60x |
Competitor Companies of 300841 by Market Capitalization
Companies near Chengdu Kanghua Biological Products in the global market cap rankings as of October 6, 2026. See how leveraged is Chengdu Kanghua Biological Products's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Chengdu Kanghua Biological Products by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.62 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #379 globally with a market cap of $73.47 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.76 Billion USD ( AU$85.87 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.62 Billion | $503.50 |
| #379 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.47 Billion | $726.47 |
| #455 | CSL Ltd | AU:CSL | $60.76 Billion | AU$176.99 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $203.21 |
Chengdu Kanghua Biological Products Historical Marketcap From 2020 to 2026
Between 2020 and today, Chengdu Kanghua Biological Products's market cap moved from $3.73 Billion to $ 1.07 Billion, with a yearly change of 4.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.07 Billion | -22.00% |
| 2025 | CN¥1.37 Billion | +32.54% |
| 2024 | CN¥1.04 Billion | -27.49% |
| 2023 | CN¥1.43 Billion | -7.82% |
| 2022 | CN¥1.55 Billion | -39.24% |
| 2021 | CN¥2.55 Billion | -31.64% |
| 2020 | CN¥3.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 6th, 2026 the market cap of Chengdu Kanghua Biological Products was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.07 Billion USD |
| MoneyControl | $1.07 Billion USD |
| MarketWatch | $1.07 Billion USD |
| marketcap.company | $1.07 Billion USD |
| Reuters | $1.07 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more